# Sources — Jacqueline du Pré

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 5, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. “The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History.” *Multiple Sclerosis Journal – Experimental, Translational and Clinical* 2018;4(2):2055217318775756 (PMID 29780612). Supports her birth in Oxford on 26 January 1945 to musician parents; the Suggia scholarship at 11 and the Queen’s Prize; the 1965 Elgar recording with the London Symphony Orchestra under Barbirolli; her return to England with profound exhaustion in 1971 and worsening finger numbness with fatigue in 1972; the diagnosis of multiple sclerosis in London in October 1973, four years after the onset of symptoms; corticosteroids as the treatment then available, and the absence of public medical records; her teaching; the OBE in 1976; and her death on 19 October 1987 at 42. It gives the year of her last concert as 1972, which the other sources contradict; that detail is not used. https://pmc.ncbi.nlm.nih.gov/articles/PMC5952293/
2. Dacy LC, Rodriguez M (Mayo Clinic). “The interrupted concerto: Jacqueline du Pré and MS.” *Hektoen International*, Fall 2014. Supports episodes of blurred vision in her teens, read by the authors as possibly an early sign of MS; fatigue and finger paresthesia; the Elgar Concerto in London in February 1973 as almost her last public performance; steroids as the treatment of acute attacks; the authors’ reading of her course as relapsing-remitting with secondary progression; teaching after she stopped performing; and her fundraising for MS research and the fellowships in her name. https://hekint.org/?p=2751
3. Wikipedia. “Jacqueline du Pré.” Used for her full name, birth date and place, her mother’s training at the Royal Academy of Music and her father’s work as an accountant; study with William Pleeth at the Guildhall School of Music, the Suggia Award in 1956, the Casals masterclass in 1960 and the Wigmore Hall debut in March 1961; the 1965 Elgar recording and the Davidov Stradivarius; her conversion and marriage in June 1967; the loss of sensitivity in her fingers in 1971 and the sabbatical of 1971 to 1972; her last public concerts in February 1973; the diagnosis in October 1973; teaching until her death; the OBE in the 1976 New Year Honours; and her death in London on 19 October 1987 and burial at Golders Green Jewish Cemetery. https://en.wikipedia.org/wiki/Jacqueline_du_Pr%C3%A9
4. “du Pré, Jacqueline (1945–1987).” *Women in World History: A Biographical Encyclopedia* (Gale), via Encyclopedia.com. Supports her birth date and place, her early training, the Guildhall Gold Medal and Queen’s Prize at 15, the Wigmore Hall debut at 16, persistent fatigue before the diagnosis, her master classes after the diagnosis (“she whistled the musical parts and explained the fingering to her students”), and her death in London of multiple sclerosis, which it dates to 20 October 1987. https://www.encyclopedia.com/women/encyclopedias-almanacs-transcripts-and-maps/du-pre-jacqueline-1945-1987
5. HISTMED Master Roster v3. Internal project source. Its entries were provisional and were not treated as independent corroboration.

## Clinical guidance

1. Rae-Grant A, et al. “Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis.” *Neurology* 2018;90(17):777–788 (PMID 29686116). Offering disease-modifying therapy to people with relapsing MS, high-efficacy therapy for highly active disease, and counseling on reproductive plans. https://pubmed.ncbi.nlm.nih.gov/29686116/
2. Montalban X, et al. “ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.” *Mult Scler* 2018;24(2):96–120 (PMID 29353550). Early treatment, high-efficacy drugs for active disease, JCV antibody status in the choice of natalizumab, MRI monitoring, and pregnancy planning. https://pubmed.ncbi.nlm.nih.gov/29353550/
3. National Institute for Health and Care Excellence. “Multiple sclerosis in adults: management” (NG220, 2022). Diagnosis by a neurologist with the McDonald criteria, written information and a named contact, relapse treatment with oral methylprednisolone 500 mg daily for 5 days (intravenous 1 g daily for 3 to 5 days when oral treatment is unsuitable), exclusion of infection before steroids, fatigue management with exercise and energy management, and occupational therapy. The NICE pages could not be fetched (403); the page URL resolves and the recommendations were checked against published summaries. https://www.nice.org.uk/guidance/ng220
4. Thompson AJ, et al. “Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.” *Lancet Neurol* 2018;17(2):162–173 (PMID 29275977). https://pubmed.ncbi.nlm.nih.gov/29275977/
5. Montalban X, et al. “Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria.” *Lancet Neurol* 2025;24(10):850–865 (doi:10.1016/S1474-4422(25)00270-4). Published in September 2025: the optic nerve as a fifth region, dissemination in time no longer always required, and the central vein sign, paramagnetic rim lesions and kappa free light chains as supporting evidence. No PubMed record was retrieved; the DOI resolves to the publisher. https://doi.org/10.1016/S1474-4422(25)00270-4
6. Wattjes MP, et al. “2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.” *Lancet Neurol* 2021;20(8):653–670 (PMID 34139157). Brain and spinal MRI with gadolinium at diagnosis, a re-baseline scan three to six months after starting therapy, and yearly brain MRI. https://pubmed.ncbi.nlm.nih.gov/34139157/
7. Wingerchuk DM, et al. “International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.” *Neurology* 2015;85(2):177–189 (PMID 26092914). Aquaporin-4 IgG by cell-based assay. https://pubmed.ncbi.nlm.nih.gov/26092914/
8. Hauser SL, et al. “Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.” *N Engl J Med* 2017;376(3):221–234 (PMID 28002679). Dosing, infusion reactions and infections. https://pubmed.ncbi.nlm.nih.gov/28002679/
9. Farez MF, et al. “Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis.” *Neurology* 2019;93(13):584–594 (PMID 31462584). Vaccination before immunosuppressive therapy and avoidance of live vaccines on it. https://pubmed.ncbi.nlm.nih.gov/31462584/
10. Gupta K, et al. IDSA and ESCMID guideline for acute uncomplicated cystitis and pyelonephritis in women. *Clin Infect Dis* 2011;52(5):e103–e120 (PMID 21292654). Nitrofurantoin for 5 days (used at the sick visit). https://pubmed.ncbi.nlm.nih.gov/21292654/
11. U.S. Preventive Services Task Force: depression (2023), cervical cancer (2018), intimate partner violence (2018), unhealthy alcohol use (2018), and the A and B recommendations; Centers for Disease Control and Prevention, Adult Immunization Schedule by Medical Condition; Medicare Preventive Services reference (Aether Forge, 2026). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations, https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-medical-condition.html, https://patrickrutledge.github.io/preventative_services/

The CMID has no multiple sclerosis monograph, so the specialty guidelines above govern the monitoring, and GL-CMID-2026 is not cited.

## Editorial resolutions

- **Recent-death rule and living relatives.** She died in 1987, before the rule’s threshold, so it does not apply. Her husband and her siblings, however, are living or recently living public people. None of them is named anywhere in the record; her husband appears only as “her husband, a pianist and conductor,” in the documented history of her marriage (CLM-0004) and in the modern household, with no role, statement or health fact. The family memoir and the claims drawn from it, an account attributed to her husband of how her first symptoms began, and later disputed claims about her death are not used at all.
- **Sources not used.** The Jacqueline du Pré Charitable Trust, the MS Society UK and the Royal Academy of Music pages on her were not found; the *New York Times* obituary could not be fetched; the *Guardian* obituary was not found; Britannica and the Jewish Women’s Archive could not be fetched (403). Elizabeth Wilson’s biography was not read, and no reliable quotation of its medical account was found; it is not cited. The 2018 review cites Carol Easton’s biography, which was not read.
- **Name.** The display name is Jacqueline du Pré. Splitting at the last space would make “Jacqueline du” her given names. The record uses identity.name_parts with given names Jacqueline Mary and the family name “du Pré” (lower-case particle), so the C-CDA and FHIR names are correct; the notes call her Ms. du Pré. Aliases are Jacqueline Mary du Pré and the unaccented Jacqueline du Pre; neither appears in another record. Her family nickname is not used as an alias, because it is part of another figure’s name in this batch.
- **Death date.** 19 October 1987 (Wikipedia, the 2018 review); Women in World History gives 20 October, the date of the *New York Times* obituary, recorded as a conflicting alternative.
- **Index age and dates.** The synthetic date of birth is 26 January 1998 (shift 53 years). The index visit on 9 March 2026 maps to 9 March 1973, when she was 28: after her last public concerts in London and New York in February 1973 and before the documented diagnosis in London in October 1973. All visits map to March to October 1973, within her lifetime; they are not a claim about where she was. The modern diagnosis comes two weeks after the first visit rather than four years after the first symptoms, which is the intended contrast.
- **Intake claims.** The 1971 loss of sensation and fatigue (CLM-0005), the teen-age visual episodes (CLM-0006, R) and the last concerts (CLM-0007) appear in the intake documents; the diagnosis (CLM-0008), the course (CLM-0010, R) and later events are linked to later timeline events.
- **Presenting problem.** Numbness and clumsiness of the hands with Lhermitte’s sign (R20.2) is resolved at the diagnosis visit on 23 March 2026, when relapsing-remitting multiple sclerosis (G35.A, both_with_link) and vitamin D deficiency (E55.9) are recorded. G35.A is the FY2026 ICD-10-CM code for relapsing-remitting MS. The intake documents state only what was known then.
- **Earlier episode.** The synthetic history of a month of finger tingling 18 months before the first visit is anchored to her documented loss of sensation in her fingers in 1971. The teen-age blurred vision noted by the Mayo authors (CLM-0006) is R and is not used in the modern history; nor is the account of a thigh numbness after anesthesia, which rests on her husband’s recollection.
- **Diagnostic choices.** Aquaporin-4 antibody was tested because the presentation is a myelitis; MOG antibody was not, because nothing in the picture suggests MOG antibody disease. The 2024 McDonald revision was published (Lancet Neurology, September 2025) and is cited alongside the 2017 criteria; she meets both.
- **Disease-modifying therapy.** Ocrelizumab was chosen as early high-efficacy therapy for active disease: natalizumab was set aside because her JCV antibody is positive (index 1.4), and ofatumumab, equally reasonable, was declined at her preference for twice-yearly infusions given her travel. This is a teaching choice for review.
- **Relapse treatment.** Intravenous methylprednisolone 1 g daily for 3 days was used; NICE NG220 prefers oral methylprednisolone 500 mg daily for 5 days, which the consultant names as an equivalent alternative. This is a judgment call for review.
- **Vaccination timing.** PCV20, the first recombinant zoster dose and the first hepatitis B dose were given three weeks before the first infusion; the second hepatitis B dose came two weeks after B-cell depletion began and the second zoster dose three months later. Starting treatment promptly for active disease was judged more important than completing every series first; the resulting non-protective hepatitis B antibody (6 mIU/mL) is recorded and a booster deferred while B cells are depleted.
- **Synthetic clinical picture.** All visits, results, imaging, CSF findings, the JCV, hepatitis B and varicella results, nine-hole peg times (coded as NIH Toolbox nine-hole pegboard times, in seconds), EDSS scores, treatments, her height (173 cm) and weights are synthetic. Qualitative results (CSF, antibodies, serology, pregnancy and urine tests) are in note text only.
- **Sick visit.** Acute uncomplicated cystitis (N30.00) with a pseudo-relapse, seven weeks after the first ocrelizumab course, chosen because infections are more common on anti-CD20 therapy and because telling a pseudo-relapse from a relapse (and not giving steroids for it) is a core teaching point; it insinuates no undocumented real diagnosis. Treated with nitrofurantoin for 5 days.
- **Preventive visit.** A periodic adult preventive visit at 28 (CPT 99395 and 99497 in plain text): inactivated influenza and COVID-19 vaccines, live vaccines avoided on ocrelizumab, cervical screening up to date, chlamydia and gonorrhea screening not indicated over 24 without risk, contraception counseling with an IUD or implant offered, and advance care planning with an unnamed agent.
- **Focused visits.** The four chronic-care follow-ups (diagnosis and consultation, second half-dose, three months with re-baseline MRI, and six months with the first 600 mg dose) are documented as focused visits on the AAN 2018 and ECTRIMS/EAN 2018 guidelines, NICE NG220, the McDonald criteria, the 2021 MAGNIMS-CMSC-NAIMS MRI recommendations and the AAN 2019 vaccination guideline. No new diagnosis is introduced at these visits. One protocol deviation is recorded instead of an invented result: the hepatitis B surface antibody due one to two months after the second vaccine dose was not ordered; recorded at three months; no harm expected; drawn at six months (6 mIU/mL, not protective); corrective action: post-vaccination serology added to the clinic’s B-cell therapy checklist.
- **Consultation.** The neurology referral and the consultation by Rafael Lindgren-Achebe, MD (a fictional consultant), on the diagnosis day, are **S**. The consultant answers the five referral questions in line with what the record shows afterwards: relapsing-remitting MS by the 2017 and 2024 criteria with mimics excluded; intravenous methylprednisolone for the relapse; ocrelizumab, with the reasons against natalizumab and ofatumumab; screening and vaccinations before B-cell therapy, a re-baseline MRI and blood tests before infusions; occupational therapy and fatigue management; vitamin D; and pregnancy planning.
- **Music and work.** The modern plan has her return to practice, chamber performance and master classes. Her documented history is that the diagnosis ended her performing and that she taught afterwards; the modern course is a teaching contrast, not a claim about what she could have done.
- **Real people.** No relative, friend, colleague or historical physician is named or given a role in the modern episode. Her teachers (William Pleeth, Pablo Casals) and the conductor of her 1965 recording appear only in documented history. No other figure with a record in the dataset is named.
